Cerebral circulation was studied in six patients with obstructive sleep apnea (OSA) by transcranial Doppler. Cerebral blood flow velocity (CBFV), pulsatility index (Pi), intra-arterial radial blood pressure, transcutaneous blood gases, and respiration were recorded during sleep with or without apneas. There was a concomitant increase of mean arterial pressure (Pa) and CBFV by 11 +/- 6% (p < 0.001) and 15 +/- 6% (p < 0.001) compared with baseline at 5.1 +/- 2.4 and 5.3 +/- 2.6 s, respectively, after apnea termination. Pa and CBFV decreased to a minimum of -8 +/- 2% (p < 0.001) and -23 +/- 8% (p < 0.001), respectively, below baseline at 19.8 +/- 5.0 and 19.4 +/- 4.5 s after apnea. Values returned to baseline within 60 s, except during repetitive apneas, which were associated with prolonged periods of reduced Pa and CBFV. Pi changed inversely to CBFV and rose to 34 +/- 15% (p < 0.001) above baseline 19.5 +/- 5.5 s after the end of apnea because of a decrease in diastolic CBFV. There was a close correlation between Pa and CBFV (r = 0.67, p < 0.001), indicating that cerebral autoregulation is insufficient to protect the brain from rapid systemic pressure changes in OSA. The findings suggest that apneas during sleep are associated with profound changes in cerebral blood flow. Apnea-induced hypoxemia combined with reduced cerebral perfusion may predispose to nocturnal cerebral ischemia in patients with OSA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1164/ajrccm.150.6.7952619 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.
Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.
View Article and Find Full Text PDFIndirect Detection of the Protons in and around Biradicals and their Mechanistic Role in MAS-DNP.
J Phys Chem Lett
January 2025
National High Magnetic Field Laboratory, Florida State University, 1800 E. Paul Dirac Dr, Tallahassee, Florida 32310, United States.
The contribution of protons in or near biradical polarizing agents in Dynamic Nuclear Polarization (DNP) has recently been under scrutiny. Results from selective deuteration and simulations have previously suggested that the role of protons in the biradical molecule depends on the strength of the electron-electron coupling. Here we use the cross effect DNP mechanism to identify and acquire H solid-state NMR spectra of the protons that contribute to propagation of the hyperpolarization, via an experimental approach dubbed Nuclear-Nuclear Double Resonance (NUDOR).
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Center for Biomedical Semantics and Data Intelligence (CBSDI), University of Texas Health Science Center at Houston, Houston, TX, USA.
Background: Findings regarding the protective effect of Angiotensin II receptor blockers (ARBs) against Alzheimer's disease and related dementias (ADRD) and cognitive decline have been inconclusive.
Method: A total of 6,390,826 hypertensive individuals were included in this study from Optum's de-identified Clinformatics® Data Mart. We identified antihypertensive medication (AHM) drug classes and subclassified ARBs by blood-brain barrier (BBB) permeability.
Drug Development.
Alzheimers Dement
December 2024
Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA, USA.
Background: Participant dropout from study treatment in a clinical trial can leave a trial underpowered, produce bias in statistical analysis, and limit interpretability of study results. Retaining participants in clinical trials for the full study duration is therefore as important as participant recruitment. This analysis aims to identify the baseline characteristics of participants who discontinued during the blinded phase of one of the first and largest preclinical AD trial completed to date, the Anti-Amyloid treatment in Asymptomatic AD (A4) Study.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
NYU Grossman School of Medicine, New York, NY, USA.
Background: Apolipoprotein E4 (apoE4) has been identified as the major genetic risk factor for late onset Alzheimer's disease (AD). Our lab has demonstrated that chronic administration of Aβ12-28P, a synthetic peptide that blocks apoE4/Aβ binding, in middle-aged transgenic AD mice significantly ameliorates pathology progression, resulting in reduced Aβ plaques deposition and cerebral amyloid angiopathy (CAA) along with improved memory and cognition. However, whether blocking apoE4/Aβ interaction by Aβ12-28P also has an ameliorating effect on the neuronal and cognitive function of old AD mice where Aβ pathology has been extensively developed remains unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!